Atlas Trials

Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma

Clinical trial NCT05585996 · UNKNOWN

Trial details

NCT number
NCT05585996
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed and Refractory B-cell Lymphoma
Start date
2022-08-01
Primary completion
2025-11-01
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.